European Urology Oncology
IF
7.48
Papers
510
Papers 479
1 page of 48 pages (479 results)
Newest
#1Kim Van der Eecken (Ghent University Hospital)H-Index: 1
#2Jan Vanwelkenhuyzen (Ghent University Hospital)H-Index: 1
Last. Piet Ost (Ghent University)H-Index: 44
view all 13 authors...
Abstract null null Context null Multiple studies have reported on the genomic characteristics of metastatic hormone-sensitive prostate cancer (mHSPC). The impact of these findings on prognostication, treatment selection, and clinical trial design remains unclear. null null null Objective null To summarise genomic alteration prevalences in liquid and/or tissue biopsies, infer their clinical implications, and compare genomic alteration frequencies across different disease states and clinical pheno...
Source
#1Omar Alhalabi (The University of Texas MD Anderson Cancer Center)H-Index: 6
#2Yueting Zhu (The University of Texas MD Anderson Cancer Center)
Last. Jianjun Gao (The University of Texas MD Anderson Cancer Center)H-Index: 27
view all 28 authors...
Deficiency of MTAP (MTAPdef) mainly occurs because of homozygous loss of chromosome 9p21, which is the most common copy-number loss in metastatic urothelial cancer (mUC). We characterized the clinical and genomic features of MTAPdef mUC in 193 patients treated at MD Anderson Cancer Center (MDACC) and 298 patients from the phase 2 IMvigor210 trial, which investigated atezolizumab in cisplatin-ineligible and platinum-refractory disease. In the MDACC cohort, visceral metastases were significantly m...
Source
#1Maria Monica Ratti (Vita-Salute San Raffaele University)H-Index: 1
#2Giorgio Gandaglia (Vita-Salute San Raffaele University)H-Index: 55
Last. Alberto Briganti (Vita-Salute San Raffaele University)H-Index: 99
view all 25 authors...
Abstract null null Context null Prostate cancer (PCa) is the second most common cancer among men worldwide. Urinary, bowel, and sexual function, as well as hormonal symptoms and health-related quality of life (HRQoL), were prioritised by patients and professionals as part of a core outcome set for localised PCa regardless of treatment type. null null null Objective null To systematically review the measurement properties of patient-reported outcome measures (PROMs) used in localised PCa and reco...
Source
#1Tobias Hölscher (DKFZ: German Cancer Research Center)
#2Michael Baumann (HZDR: Helmholtz-Zentrum Dresden-Rossendorf)H-Index: 18
Last. Fabian Lohaus (DKFZ: German Cancer Research Center)H-Index: 20
view all 13 authors...
BACKGROUND Local ablative radiotherapy (aRT) of oligometastatic prostate cancer (PCa) is very promising and has become a focus of current clinical research. OBJECTIVE We hypothesize that aRT is safe and effective in gallium-68 prostate-specific membrane antigen targeted positron emission tomography (PSMA-PET)-staged oligometastatic PCa patients. DESIGN, SETTING, AND PARTICIPANTS A nonrandomized, prospective, investigator-initiated phase 2 trial recruited patients with oligometastatic PCa (five o...
Source
#1Estefania Labanca (The University of Texas MD Anderson Cancer Center)H-Index: 5
#2Jun Yang (The University of Texas MD Anderson Cancer Center)H-Index: 17
Last. Nora M. Navone (The University of Texas MD Anderson Cancer Center)H-Index: 39
view all 18 authors...
Background null No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation. null Objective null To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases. null Design, setting, and participants null In silico, in vitro, and in vivo preclinical approaches were used. RNA-seque...
Source
#1Ekaterina Laukhtina (Medical University of Vienna)H-Index: 8
#2Sung Ryul Shim (Korea University)H-Index: 1
Last. Benjamin Pradere (Medical University of Vienna)H-Index: 16
view all 22 authors...
Abstract null null Context null During the past decade, several urinary biomarker tests (UBTs) for bladder cancer have been developed and made commercially available. However, none of these is recommended by international guidelines so far. null null null Objective null To assess the diagnostic estimates of novel commercially available UBTs for diagnosis and surveillance of non–muscle-invasive bladder cancer (NMIBC) using diagnostic test accuracy (DTA) and network meta-analysis (NMA). null null ...
Source
#1Giorgio Gandaglia (Vita-Salute San Raffaele University)H-Index: 55
#2R. Leni (Vita-Salute San Raffaele University)H-Index: 2
Last. Carlo La Vecchia (UNIMI: University of Milan)H-Index: 136
view all 9 authors...
Abstract null null Context null Worldwide, prostate cancer (PCa) represents the second most common solid tumor in men. null null null Objective null To assess the geographical distribution of PCa, epidemiological differences, and the most relevant risk factors for the disease. null null null Evidence acquisition null Estimated incidence, mortality, and prevalence of PCa for the year 2020 in 185 countries were derived from the IARC GLOBOCAN database. A review of English-language articles publishe...
Source
#1Hong Truong (MSK: Memorial Sloan Kettering Cancer Center)
#2Rania Sheikh (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 2
Last. Maria I. Carlo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 20
view all 27 authors...
Abstract null null Background null Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking. null null null Objective null To define the germline genetic spectrum and clinical associations for patients with early-onset RCC diagnosed at age ≤46 yr who underwent genetic testing. null null null Design, setting, and partic...
Source
#1Nicholas Raison (Imperial College Healthcare NHS Trust)
#2Suks Minhas (Imperial College Healthcare NHS Trust)H-Index: 31
Source
#1Marc A. Bjurlin (UNC: University of North Carolina at Chapel Hill)H-Index: 6
#2Richard S. Matulewicz (NYU: New York University)H-Index: 14
Last. Omar El Shahawy (NYU: New York University)H-Index: 8
view all 8 authors...
Abstract Context Use of electronic cigarettes (e-cigarettes) has rapidly increased despite unclear longitudinal health effects. Once thought to be a safer alternative to tobacco smoke, it is possible that e-cigarettes expose the user to similar carcinogenic byproducts during the vaping process. These toxicants are metabolized and excreted in the urine, and may have oncogenic implications for bladder urothelium. Objective To characterize and summarize known urinary carcinogenic biomarkers in e-ci...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.